Laura Prendergast
Stock Analyst at Stifel Nicolaus
(4.83)
# 424
Out of 4,659 analysts
79
Total ratings
67.7%
Success rate
49.7%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Laura Prendergast
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| STRO Sutro Biopharma | Maintained: Buy | $48 | $22.04 | +117.79% | 2 | Aug 17, 2026 | |
| TNGX Tango Therapeutics | Maintained: Buy | $40 | $25.44 | +57.23% | 10 | Aug 17, 2026 | |
| FHTX Foghorn Therapeutics | Maintained: Buy | $12 | $6.75 | +77.78% | 7 | Aug 17, 2026 | |
| ERAS Erasca | Maintained: Buy | $30 | $18.10 | +65.75% | 12 | Aug 17, 2026 | |
| BDTX Black Diamond Therapeutics | Maintained: Buy | $8 | $2.06 | +288.35% | 7 | Aug 6, 2026 | |
| RVMD Revolution Medicines | Maintained: Buy | $215 | $216.00 | -0.46% | 20 | Aug 6, 2026 | |
| ORIC ORIC Pharmaceuticals | Maintained: Buy | $14 | $13.92 | +0.57% | 2 | Aug 4, 2026 | |
| COGT Cogent Biosciences | Maintained: Buy | $45 | $37.40 | +20.32% | 9 | Jun 15, 2026 | |
| BBOT BridgeBio Oncology Therapeutics | Maintained: Buy | $23 | $8.95 | +156.98% | 4 | May 13, 2026 | |
| OLMA Olema Pharmaceuticals | Initiated Coverage: Buy | $48 | $10.65 | +350.70% | 1 | Feb 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $12 | $12.73 | n/a | 3 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $4 | $9.50 | n/a | 1 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $16 | $2.41 | n/a | 1 | Aug 14, 2024 |
Sutro Biopharma
Aug 17, 2026
Maintained: Buy
Price Target: $48
Current: $22.04
Upside: +117.79%
Tango Therapeutics
Aug 17, 2026
Maintained: Buy
Price Target: $40
Current: $25.44
Upside: +57.23%
Foghorn Therapeutics
Aug 17, 2026
Maintained: Buy
Price Target: $12
Current: $6.75
Upside: +77.78%
Erasca
Aug 17, 2026
Maintained: Buy
Price Target: $30
Current: $18.10
Upside: +65.75%
Black Diamond Therapeutics
Aug 6, 2026
Maintained: Buy
Price Target: $8
Current: $2.06
Upside: +288.35%
Revolution Medicines
Aug 6, 2026
Maintained: Buy
Price Target: $215
Current: $216.00
Upside: -0.46%
ORIC Pharmaceuticals
Aug 4, 2026
Maintained: Buy
Price Target: $14
Current: $13.92
Upside: +0.57%
Cogent Biosciences
Jun 15, 2026
Maintained: Buy
Price Target: $45
Current: $37.40
Upside: +20.32%
BridgeBio Oncology Therapeutics
May 13, 2026
Maintained: Buy
Price Target: $23
Current: $8.95
Upside: +156.98%
Olema Pharmaceuticals
Feb 11, 2026
Initiated Coverage: Buy
Price Target: $48
Current: $10.65
Upside: +350.70%
Jul 29, 2025
Maintained: Buy
Price Target: $12
Current: $12.73
Upside: n/a
Feb 13, 2025
Maintained: Buy
Price Target: $4
Current: $9.50
Upside: n/a
Aug 14, 2024
Upgraded: Buy
Price Target: $16
Current: $2.41
Upside: n/a